Last €81.50 EUR
Change Today -0.41 / -0.50%
Volume 46.3K
BIM On Other Exchanges
Symbol
Exchange
BIM is not on other exchanges.
As of 11:35 AM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Open
€82.01
Previous Close
€81.91
Day High
€82.10
Day Low
€81.22
52 Week High
05/30/14 - €83.95
52 Week Low
10/18/13 - €70.65
Market Cap
3.2B
Average Volume 10 Days
22.3K
EPS TTM
€3.46
Shares Outstanding
39.5M
EX-Date
06/3/14
P/E TM
23.6x
Dividend
€1.00
Dividend Yield
1.23%
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux SA designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, or autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret the biological test results; and related services, such as the installation and maintenance of instruments, user training, or the audit of laboratory workflows. It offers diagnostic systems for clinical applications, including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples, such as blood, saliva, and urine; and for industrial applications, including the analysis of microbiological manufacturing, such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private-sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality-control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. The company was formerly known as B-D Mérieux and changed its name to bioMérieux SA. The company was founded in 1963 and is headquartered in Marcy l’Etoile, France. bioMérieux SA is a subsidiary of Institut Mérieux.

8,535 Employees
Last Reported Date: 09/5/14
Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €544.9K
Compensation as of Fiscal Year 2013.

biomerieux (BIM) Key Developments

bioMérieux Announces Audited Consolidated Earnings Results for the Six Months Ended June 30, 2014; Provides Earnings Guidance for 2014

bioMérieux announced audited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported sales of €781 million against €754 million a year ago. Operating income before non-recurring items was €79.4 million against €125.1 million a year ago. Operating income was €81 million against €124 million a year ago. Net income attributable to the parent company was €52.3 million or €1.32 per basic and diluted share against €79.7 million or €2.02 per basic and diluted share a year ago. Net cash flow from operations was €107.1 million against €101.7 million a year ago. Purchase of property, plant and equipment was €56.1 million against €59.6 million a year ago. Free cash flow was €69 million against €42 million a year ago. EBITDA (before non-recurring items) was €140.9 million against €169.0 million a year ago. In 2014, the company expects to report sales growth of between 3% and 5% for the year, at constant exchange rates and scope of consolidation. The company demonstrates the resilience of its business model, based on the technological and geographic diversification of its business base. In addition, backed by its sales momentum and the implementation of an operating cost control plan, the company maintains its target to achieve contributive operating income before non-recurring items of between €220 million and €245 million.

ATCC and bioMérieux Collaborate to Deliver Accurate Identification of Industrial Microorganisms

ATCC and bioMérieux announced their collaboration to expand and solidify the bioMérieux VITEK(R) MS microbial identification database for the industrial market. Recently, ATCC acquired the bioMérieux VITEK(R) MS system to make this innovative MALDI TOF technology a fundamental component of their authentication and quality control processes. Strengthening the database with additional strains continues to increase the robustness of the VITEK(R) MS micro-organisms library while increasing the size and enhancing the utility for customers as a solid quality assurance tool. The integration of the bioMérieux VITEK(R) MS into ATCC's quality development process will enable ATCC to generate a large pathogen knowledgebase, which will then be incorporated into the VITEK(R) MS database. The newly expanded database will improve the accuracy and range of microbial identification of the bioMérieux VITEK(R) MS.

bioMérieux Announces VIRTUO(TM)

bioMérieux announced that VIRTUO(TM), the new generation of BacT/ALERT(R), has been CE-marked. This uniquely innovative automated blood culture microbial detection system further enriches the offering of the BacT/ALERT(R) product range and is now commercially available in targeted countries that recognize CE marking. The enhanced performance of the system will help laboratories provide rapid results to clinicians to help maximize laboratory efficiency and facilitate better patient outcomes. VIRTUO(TM) is the first continuously monitoring blood culture microbial detection system to offer "set and forget" loading, allowing personnel with any skill level to load the instrument any time throughout the day and night, thus enabling even more rapid results and improved patient care. With VIRTUO(TM), laboratories minimize hands-on time and maximize laboratory efficiency: when bottles are placed on the conveyor belt of the motion-activated loading bay, the conveyor belt feeds bottles via a carousel into a smart scanning station where the bottle barcodes are read and an image of the labels is captured. The system uses precision robotics to load all bottles into available cells for incubation and determination of a blood stream infection. Following a five-day protocol, negative bottles are automatically discarded into a waste bin. VIRTUO(TM) offers a faster time to detection versus the current BacT/ALERT(R) due to the inclusion of high fidelity optics and a new detection algorithm which has shown faster detection times on average four hours earlier compared to the BacT/ALERT(R) 3D. This reduction in time to detection facilitates the ability to positively impact patient care. In line with ever increasing accreditation standards, the new target VIRTUO(TM) system, along with new reagent labeling, enables features to automatically track lot numbers, check for expired bottles and measure the sample volume to help ensure compliance with the collection of the recommended blood volume of 10ml per bottle. This next generation BacT/ALERT(R) system utilizes proven blood culture reagent bottles for increased recovery of organisms associated with blood stream infections. Currently included in the BacT/ALERT(R) media portfolio are the standard, charcoal based FAN and the new FAN Plus bottles, which use proprietary Adsorbent Polymeric Beads (APB). BacT/ALERT(R) has a large installed base of automated blood culture systems in every region in the world. The BacT/ALERT(R) range of systems makes it possible to meet the needs of all sizes of laboratories due to the flexibility and scalability of the instrument portfolio. The VIRTUO(TM) launch will initially be focused on current customers as bioMérieux's number one priority until the Company comes back to a satisfactory level of bottle media supply. The combination of substantial operational and capital investments in the Durham (N.C., United States) facility for bottle media production and the launch of this new VIRTUO(TM) instrument demonstrates bioMérieux's commitment to blood culture and the rapid reliable diagnosis of sepsis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €81.50 EUR -0.41

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $40.48 USD -0.66
Bio-Rad Laboratories Inc $117.67 USD -0.16
Hologic Inc $24.44 USD -0.13
QIAGEN NV €18.04 EUR -0.06
Siemens Ltd 859.80 INR -23.15
View Industry Companies
 

Industry Analysis

BIM

Industry Average

Valuation BIM Industry Range
Price/Earnings 22.4x
Price/Sales 1.9x
Price/Book 2.4x
Price/Cash Flow 21.4x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit www.biomerieux.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.